
In future years, more US patients will start treatment with Teva's migraine drug Ajovy.
According to Danish newspaper Børsen, Teva's new goal is that the drug, which competes with other drugs such as Danish firm Lundbeck's Vyepti, will reach a 33 percent market share in the US.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app